Y-mAbs Therapeutics, Inc.

Contributing Author

Recent Articles by Y-mAbs Therapeutics, Inc.

Aug-08	Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments GlobeNewswire
Aug-07	Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025 GlobeNewswire
Aug-05	SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics GlobeNewswire
May-28	Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline GlobeNewswire
May-26	Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting GlobeNewswire
May-13	Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025 GlobeNewswire
May-13	Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments GlobeNewswire
May-07	Y-mAbs Announces Update to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA) GlobeNewswire
May-06	Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025 GlobeNewswire